Search Results
Results found for "Jürgen Wess"
- Targeted Drug Design through GPCR Mutagenesis: Insights from β2AR
Understanding the evolutionary conservation of these residues can lead to the development of drugs that are less
- Decoding Schild Analysis: The Pharmacologist’s Lens on Competitive Antagonism
Extending Schild to Partial Agonists Partial agonists complicate things—they activate receptors but less
- Accelerating GPCR Drug Discovery: What 40 Years of Pharmacology Reveal
It’s less bureaucratic than most outsiders think.
- How Advanced GPCR Kinetics Sharpen Decision Making (and Save You Time)
It’s built for the GPCR community—by people who live the science—so you spend less time sifting and more
- 📰 GPCR Weekly News, June 5 to 11, 2023
Reviews, GPCRs, and more Diversification processes of teleost intron-less opsin genes.
- Assay Sensitivity: The Hidden Lever Driving GPCR Drug Discovery
Can changing receptor density predict how your drug will behave across sensitive versus less sensitive
- Biased Agonism at the GLP-1 Receptor: A Pathway to Improved Therapeutic Outcomes
These agonists exhibit less interaction with ECL3, resulting in an open conformation of the TM6-ECL3-
- Drug Discovery Pharmacology Principles That Turn Assays Into Real Medicines
maximal response may be estimated rather than exact In practice, the precise maximal signal matters less
- 📢 Early Bird Registration Ends Tomorrow! | Sep 16 - 22, 2024
This is your chance to get the whole experience of our comprehensive pharmacology courses for less!
- 📰 GPCR Weekly News, July 1 to 7, 2024
Submit your abstract today; you have less than two weeks!
- The Moment Biotech Founders Realize the Money Is Gone
Yet financial control is already weakening , because the company is becoming less flexible with every
- GPCRs are not simple on-off switches: deep dive into GPCR-ligand interactions
exhibit varying degrees of negative intrinsic efficacy, leading to the presence of both robust and less
- A robust and Efficient FRET-Based Assay for Cannabinoid Receptor Ligands Discovery.
.; Weise, M.; Hoare, B. L.; Miljuš, T.; Mexi, M.; Roth, N.; Koers, E. T.; Hess, C.; Madea, B.; Meiler, J.; Müller, C. E.
- Biotech Startup Failure: Why Teams Drift Off Course Without a Single Wrong Decision
. ✅ The organization is working harder to achieve less clarity .
- The Hidden Cost of Unclear Biotech Positioning
External stakeholders can decide faster, and founders waste less energy trying to adapt. ✅ If every conversation
- How Early Strategic Decision Making Creates Alignment and Better Results
When early decisions are clear, teams spend less energy interpreting what matters and more energy moving
- Targeting Intracellular Allosteric Sites in GPCRs
ligands that bind directly to the receptor's active site, allosteric modulators target distinct, often less
- Why Fundraising Mistakes Kill Strong Biotech Startups
Teams execute faster but understand less clearly why certain priorities exist, creating silent friction
- Transformative GPCR Insights: Unleash New Horizons in Science | Sep 9 - 15, 2024
This Week’s Highlights: Celebrating Excellence: Wessel A. C.
- Feeder or trigger – CCR2 as a scavenger and regulator of cell migration
Although less characterized, canonical chemokine receptor systems have been also shown to not only directly
- Unlocking the Therapeutic Potential of Previously Undruggable GPCRs
GPCRs are valuable drug targets linked to serious diseases, many remain undrugged because they are less While the native ligand conjugate exhibited poor selectivity for CCR5-expressing cells and was less effective
- Decoding β-Arrestins: from Structure to function
Cryo-EM, on the other hand, requires less protein and has evolved to achieve resolutions comparable to
















